🇺🇸 Ezetimibe + Atorvastatin in United States

23 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 23

Most-reported reactions

1. Cardiac Failure — 3 reports (13.04%)
2. Drug Intolerance — 3 reports (13.04%)
3. Myalgia — 3 reports (13.04%)
4. Blood Creatine Phosphokinase Increased — 2 reports (8.7%)
5. Cardiovascular Disorder — 2 reports (8.7%)
6. Colitis — 2 reports (8.7%)
7. Drug Effect Incomplete — 2 reports (8.7%)
8. Drug Interaction — 2 reports (8.7%)
9. Dyspnoea Exertional — 2 reports (8.7%)
10. Fatigue — 2 reports (8.7%)

Source database →

Frequently asked questions

Is Ezetimibe + Atorvastatin approved in United States?

Ezetimibe + Atorvastatin does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Ezetimibe + Atorvastatin in United States?

Organon and Co is the originator. The local marketing authorisation holder may differ — check the official source linked above.